연구성과로 돌아가기

2023 연구자 정보 (54 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Albring, Joern C.
(Albring, JC) ⓘ 		Univ Munster, Munster, Germany ⓘ
ⓘ 		0000-0002-5534-7250
Albring, Jorn ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Aouad, Pascale
(Aouad, P) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Arbune, Manuela
(Arbune, M) ⓘ 		Sf Cuv Parascheva Infect Dis Clin Hosp, Galati, Romania ⓘ C-1258-2015
Arbune, Manuela ⓘ
ⓘ 		[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Arizpe, Andre
(Arizpe, A) ⓘ 		Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med,Sch Med, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Arkenau, Hendrik-Tobias
(Arkenau, HT) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Atsukawa, Masanori
(Atsukawa, M) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Baek, Seung-Min
(Baek, SM) ⓘ 		Chungnam Natl Univ, Dept Smart Agr Syst, Daejeon 34134, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Application of auto power shift (APS) controller for minimizing fuel consumption and performance evaluation of an agricultural tractor ⓘ SCIE ⓘ 1.7 AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS ⓘ babina@cnu.ac.kr;taek.kim@tym.world; ⓘ
Baek, Seung-Yun
(Baek, SY) ⓘ 		Chungnam Natl Univ, Dept Smart Agr Syst, Daejeon 34134, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Application of auto power shift (APS) controller for minimizing fuel consumption and performance evaluation of an agricultural tractor ⓘ SCIE ⓘ 1.7 AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS ⓘ babina@cnu.ac.kr;taek.kim@tym.world; ⓘ
Baek, Yang-Hyun
(Baek, YH) ⓘ 		Dong A Univ, Coll Med, Busan, South Korea
Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
[JCR상위 1.7] Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
[JCR상위 1.7] Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ noshin@hanyang.ac.kr;
gongori1004@gmail.com; ⓘ
Bharat, Ankit
(Bharat, A) ⓘ 		Northwestern Univ, Feinberg Sch Med, Chicago, IL 60208 USA
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
Northwestern Univ, Feinberg Sch Med, Dept Thorac Surg, Arkes Pavil,676 N St Clair St Ste 2140, Chicago, IL 60611 USA
Northwestern Mem Hosp, Dept Internal Med, Chicago, IL 60611 USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer
[JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.
[JCR상위 67.0] Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer
[JCR상위 21.0] Current and future role of double-lung transplantation for bilateral lung cancer
[JCR상위 19.0] A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
SURGERY;TRANSPLANTATION
IMMUNOLOGY;TRANSPLANTATION ⓘ 		ankit.bharat@nm.org;ychae@nm.org;
ankit.bharat@nm.org;YCHAE@nm.org;
ychae@nm.org; ⓘ
Boku, Narikazu
(Boku, N) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Bruno, Benedetto
(Bruno, B) ⓘ 		ⓘ K-1392-2018
Bruno, Benedetto ⓘ 		0000-0002-7299-6770
Bruno, Benedetto ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Bulabois, Claude-Eric
(Bulabois, CE) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Cameron, David A.
(Cameron, DA) ⓘ 		ⓘ C-7781-2013
Cameron, David ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Cathcart, Andrea
(Cathcart, A) ⓘ 		Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med,Sch Med, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
페이지 이동: